-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 1, 2021, Synthekine announced that it has reached a global research cooperation and licensing agreement with Merck & Co.
(MSD)
.
The collaboration will use Synthekine's proprietary alternative cytokine agonist technology platform to discover, develop and commercialize new cytokine therapeutic drugs
According to the terms of the agreement, Synthekine and Merck will jointly take charge of the initial research work, and Merck will have the development, production and commercialization rights of alternative cytokine agonists for up to two cytokine targets
.
Synthekine will be eligible for development, regulatory and commercialization milestones of up to $525 million, as well as tiered royalties on net sales for each target, and Merck will also provide research funding for Synthekine
Synthekine focuses on immunological research, based on structural insights into cytokines, combined with a variety of engineering techniques to develop optimized therapies for cytokine targets, mainly for the treatment of cancer and autoimmune diseases
.
These new immunotherapies include modified cytokines, cytokine-enhanced cell therapies, and alternative cytokine agonists
Cytokines are small molecular proteins that allow immune cells to "communicate", and are the core of the body's response to diseases and maintaining immune homeostasis
.
However, the development of cytokines as therapeutic drugs is challenging because cytokines are pleiotropic, which means that they can induce a series of responses in different cell types, leading to reduced efficacy or dose-limiting toxicity
Reference materials:
[1] Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform.
